Novo Nordisk (NVO) Financial Analysis & Valuation | Quarter Chart
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obe... more
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufactu... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $172.90B | Exchange | NYSE |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DK | CEO | Maziar Mike Doustdar |
| IPO Date | 1981-04-30 | CAGR | 11.37% |
| Employees | 68,794 | Website | www.novonordisk.com |
| Div. Yield | 283.76% | Payout Ratio | 45% |
| Buy Back Yield | 205.68% | Total Yield | 489.44% |
NVO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $1457.08B | P/E | 9.74 | Forward P/E | 1.71 | PEG | -0.46 |
| P/S | 0.06 | P/B | 0.08 | P/CF | 0.14 | P/FCF | 0.37 |
| Sales | $50.93B | Sales 1Y | 5.61% | Sales 3Y | 63.63% | Sales 5Y | 153.58% |
| EPS | $4.02 | EPS 1Y | 5.01% | EPS 3Y | 75.77% | EPS 5Y | 173.67% |
| Sales QoQ | -18.94% | EPS QoQ | -56.55% | Sales QoQ Avg | 1.63% | EPS QoQ Avg | 8.45% |
| Gross Margin | 80.65% | Operating Margin | 43.13% | Profit Margin | 35.35% | ROCE | 39.93% |
| ROA | 20% | ROE | 59% | Altman Z Score | 3.88 | Piotroski Score | 6 |
| Current Ratio | 0.87 | Quick Ratio | 0.66 | Cash Ratio | 0.19 | Op. CF Ratio | 0.23 |
| Debt/Equity | 0.63 | Debt/Assets | 0.24 | Lt Debt/Equity | 0.55 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | 86.86 | Inventory Turnover | 1.24 | Asset Turnover | 0.55 | Receivables Turnover | 3.04 |
| Enterprise Value | $1457.08B | P/E Ratio | 9.74 |
| Forward P/E | 1.71 | PEG Ratio | -0.46 |
| P/S Ratio | 0.06 | P/B Ratio | 0.08 |
| P/CF Ratio | 0.14 | P/FCF Ratio | 0.37 |
| EPS | $4.02 | EPS Growth 1Y | 5.01% |
| EPS Growth 3Y | 75.77% | EPS Growth 5Y | 173.67% |
| Revenue Growth 1Y | 5.61% | Gross Margin | 80.65% |
| Operating Margin | 43.13% | Profit Margin | 35.35% |
| ROE | 59% | ROA | 20% |
| ROCE | 39.93% | Current Ratio | 0.87 |
| Quick Ratio | 0.66 | Cash Ratio | 0.19 |
| Debt/Equity | 0.63 | Interest Coverage | 86.86 |
| Altman Z Score | 3.88 | Piotroski Score | 6 |
Novo Nordisk (NVO) valuation & financials
Novo Nordisk (NVO) has a market capitalization of $172.90B and trades at a price-to-earnings ratio of 9.7. It operates in the Healthcare sector (Biotechnology).
Novo Nordisk's revenue grew +5.6% over the last year.
Novo Nordisk's next earnings report is scheduled for November 4, 2026 before market open (provider scheduled date); analysts estimate EPS of $0.74. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)